Dark

Check out our API

PSTV
PLUS THERAPEUTICS, Inc. Common Stock
stock NASDAQ

At Close

Jun 18, 2026 3:59:30 PM EDT

4.22USD-2.088%(-0.09)214,523

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 18, 2026 9:18:30 AM EDT

4.35USD+0.928%(+0.04)532

After-hours

Jun 18, 2026 4:22:30 PM EDT

4.25USD+0.711%(+0.03)20,842

OverviewHistoricalExchangesShortsTrends

PSTV Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

PSTV Specific Mentions

As of Jun 19, 2026 3:29:57 PM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

2 days ago • u/DadInTheShadows19 • r/stockstobuytoday • bottlenecks_and_overlooked_stocks • C

PSTV is brewing and a gift under $5 right now.
Q3 2026 Catalysts
REYOBIQ (ReSPECT-LM Trial): Release interim data on optimal dose and dosing intervals
CNSide Assay: Expand U.S. commercial payer coverage toward the target of 150 million covered lives.
Q4 2026 Catalysts
REYOBIQ (ReSPECT-GBM Trial): Complete patient enrollment and release expected data for recurrent Glioblastoma.
FDA Engagement: Conduct an End-of-Phase meeting with the FDA to align on the Phase 3 pivotal trial design.
Commercial Scale-Up: Reach annualized target of greater than 1,250 CNSide test orders and optimize Medicare reimbursement pathways.

3 days ago • u/After_Revolution_960 • r/stockstobuytoday • bottlenecks_and_overlooked_stocks • C

You still trust PSTV?

2 days ago • u/DadInTheShadows19 • r/stockstobuytoday • bottlenecks_and_overlooked_stocks • C

PSTV is brewing and a gift under $5 right now.
Q3 2026 Catalysts
REYOBIQ (ReSPECT-LM Trial): Release interim data on optimal dose and dosing intervals
CNSide Assay: Expand U.S. commercial payer coverage toward the target of 150 million covered lives.
Q4 2026 Catalysts
REYOBIQ (ReSPECT-GBM Trial): Complete patient enrollment and release expected data for recurrent Glioblastoma.
FDA Engagement: Conduct an End-of-Phase meeting with the FDA to align on the Phase 3 pivotal trial design.
Commercial Scale-Up: Reach annualized target of greater than 1,250 CNSide test orders and optimize Medicare reimbursement pathways.

3 days ago • u/After_Revolution_960 • r/stockstobuytoday • bottlenecks_and_overlooked_stocks • C

You still trust PSTV?

Share